Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

v3.19.3
Revenue - Narrative (Details)
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 08, 2018
USD ($)
Feb. 08, 2018
USD ($)
swap_option
Feb. 08, 2018
USD ($)
Feb. 08, 2018
USD ($)
research_program
Feb. 08, 2018
USD ($)
performance_obligation
Feb. 08, 2018
USD ($)
license
May 02, 2017
USD ($)
performance_obligation
Feb. 27, 2017
USD ($)
Jan. 04, 2017
EUR (€)
bispecific_therapeutic_program
performance_obligation
extension_option
license
Jan. 04, 2017
USD ($)
bispecific_therapeutic_program
performance_obligation
extension_option
product
license
Feb. 28, 2019
EUR (€)
Feb. 28, 2019
USD ($)
Dec. 31, 2018
EUR (€)
Dec. 31, 2018
USD ($)
Jan. 31, 2017
performance_obligation
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
performance_obligation
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 01, 2019
USD ($)
Disaggregation of Revenue [Line Items]                                            
Revenue recognized from contract with customer                               $ 11,000,000   $ 17,400,000        
Revenue                               14,498,000 $ 7,873,000 26,966,000 $ 22,541,000      
Deferred revenues, current portion                           $ 35,612,000   27,242,000   27,242,000   $ 35,612,000    
Deferred revenue, net of current portion                           53,303,000   44,179,000   44,179,000   53,303,000   $ 56,780,000
Additions to deferred revenue                                   0        
Seattle Genetics                                            
Disaggregation of Revenue [Line Items]                                            
Deferred revenues, current portion                               7,300,000   7,300,000        
Remaining performance obligation                               24,700,000   24,700,000        
Deferred revenue, net of current portion                               13,200,000   13,200,000        
AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Deferred revenues, current portion                               11,600,000   11,600,000        
Remaining performance obligation                               36,400,000   36,400,000        
Deferred revenue, net of current portion                               17,300,000   17,300,000        
Research collaboration agreement term             5 years                              
Capitalized contract costs             $ 1,600,000                 1,000,000   1,000,000        
Capitalized contract cost in accordance with ASC 340                               1,100,000   1,100,000        
Amortization of capitalized contract costs                                   100,000        
Les Laboratoires Servier and Institut de Recherches Internationales Servier                                            
Disaggregation of Revenue [Line Items]                                            
Deferred revenues, current portion                               5,500,000   5,500,000        
Remaining performance obligation                               19,200,000   19,200,000        
Deferred revenue, net of current portion                               13,700,000   13,700,000        
Capitalized contract costs                   $ 500,000           300,000   300,000        
Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                            
Disaggregation of Revenue [Line Items]                                            
Research collaboration agreement term                 3 years 3 years                        
ASKA Pharmaceutical Co. Ltd.                                            
Disaggregation of Revenue [Line Items]                                            
Deferred revenues, current portion                               2,800,000   2,800,000        
Capitalized contract costs               $ 300,000               300,000   $ 300,000        
Evaluation period               60 days                            
License and Collaboration Agreement | Seattle Genetics                                            
Disaggregation of Revenue [Line Items]                                            
Period after effective date agreements may be terminated 12 months                                          
Contract termination advance notice period 90 days                                          
Agreement termination advance notice period if marketing approval obtained 180 days                                          
Agreement termination notice period upon material breach by the Company 90 days                                          
Contract termination due to material breach, additional notice period if the breach is not susceptible 90 days                                          
Number of licenses (in licenses) | license           3                                
Number of swap options (in swap options) | swap_option   2                                        
Number of performance obligations       3 6                         3        
License and Collaboration Agreement | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Period after effective date agreements may be terminated             12 months                              
Contract termination advance notice period             90 days                              
Agreement termination advance notice period if marketing approval obtained             180 days                              
Agreement termination notice period upon material breach by the Company             180 days                              
Contract termination due to material breach, additional notice period if the breach is not susceptible             180 days                              
Number of performance obligations | performance_obligation             16                              
Agreement termination notice period upon breach of payment obligations by the Company             30 days                              
Performance obligation period             12 months                              
License and Collaboration Agreement | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                            
Disaggregation of Revenue [Line Items]                                            
Number of licenses (in licenses) | license                 5 5                        
Number of performance obligations | performance_obligation                 4 4         14              
Number of research programs | bispecific_therapeutic_program                 5 5                        
Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                            
Disaggregation of Revenue [Line Items]                                            
Revenue recognized from contract with customer                     € 1.5 $ 1,700,000 € 0.5 $ 600,000                
Period after effective date agreements may be terminated                 12 months 12 months                        
Contract termination advance notice period                 180 days 180 days                        
Number of collaboration products | product                   4                        
Strategic Partnerships and Other License Agreements | ASKA Pharmaceutical Co. Ltd.                                            
Disaggregation of Revenue [Line Items]                                            
Revenue recognized from contract with customer                               $ 0       $ 0 $ 0  
Agreement termination notice period upon breach of payment obligations by the Company               30 days                            
Upfront Payment | Seattle Genetics                                            
Disaggregation of Revenue [Line Items]                                            
Research and development services     $ 4,900,000                                      
Deferred revenue $ 1,200,000,000 $ 1,200,000,000 1,200,000,000 $ 1,200,000,000 $ 1,200,000,000 $ 1,200,000,000                                
Upfront Payment | Seattle Genetics | License fees                                            
Disaggregation of Revenue [Line Items]                                            
Revenue     $ 30,000,000                                      
Upfront Payment | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Allocable arrangement consideration             $ 45,000,000                              
Upfront Payment | ASKA Pharmaceutical Co. Ltd.                                            
Disaggregation of Revenue [Line Items]                                            
Upfront option payment received               $ 2,750,000                            
Upfront Payment | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier | License fees                                            
Disaggregation of Revenue [Line Items]                                            
Revenue                 € 30.0 $ 32,000,000                        
Additional Other Research Services | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Allocable arrangement consideration             4,700,000                              
Estimated Development and Manufacturing Services | Upfront Payment | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Allocable arrangement consideration             14,200,000                              
Milestone Payments | Upfront Payment | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Allocable arrangement consideration             12,500,000                              
Estimated Phase 2a Services | Upfront Payment | AstraZeneca                                            
Disaggregation of Revenue [Line Items]                                            
Allocable arrangement consideration             $ 4,700,000                              
Extension Term | Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                            
Disaggregation of Revenue [Line Items]                                            
Research collaboration agreement term                 1 year 1 year                        
Number of agreement extension options | extension_option                 2 2                        
Minimum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                            
Disaggregation of Revenue [Line Items]                                            
Agreement termination notice period upon material breach by the Company                 90 days 90 days                        
Maximum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                            
Disaggregation of Revenue [Line Items]                                            
Agreement termination notice period upon material breach by the Company                 120 days 120 days